TARX

Tarsier Pharma files Amendment No. 3 to its F-1 registration statement solely to add Exhibit 10.10…

This filing is purely administrative and carries no trading signal. Monitor for the SEC effectiveness notice and final IPO pricing, which will determine the actual market entry point for TARX shares.

Tarsier Pharma, an Israeli late clinical-stage biopharmaceutical company focused on inflammatory…

Monitor effectiveness of IPO pricing and demand; watch for initiation of Tarsier-04 trial in Q3 2026 and top-line results in 2027. The SPA agreement de-risks the regulatory pathway, but clinical…

Tarsier Pharma Ltd., an Israeli late clinical-stage biopharmaceutical company focused on…

Monitor for final IPO pricing and initial trading volume. Key catalysts: completion of the SPA-guided Tarsier-04 Phase 3 trial (expected to initiate Q3 2026), FDA interactions, and partner…